GlobeNewswire

Colliers International Creates Dominant Market Leader in Denmark

Del

Addition of premier Capital Markets firm strengthens country leadership and service offerings

TORONTO, July 03, 2018 (GLOBE NEWSWIRE) -- Leading global commercial real estate services firm Colliers International Group Inc. (NASDAQ:CIGI) (TSX:CIGI) today announced that it has acquired a controlling interest in Sadolin & Albæk ("Sadolin"), Denmark's leading capital markets specialist, which will be merged with Colliers International's current operations in Denmark ("Colliers Denmark"). The partners of Sadolin, together with the existing leadership team of Colliers Denmark, will retain a significant equity stake in the combined business under Colliers's unique enterprise partnership model. Together, Colliers Denmark will have a total of 150 professionals offering a variety of services including capital markets, corporate solutions, commercial lease and sales brokerage, urban consulting & advisory and property valuations, operating from five offices in Copenhagen, Aarhus, Vejle, Aalborg and Odense. Terms of the transaction were not disclosed.

Established in 1967, Sadolin brings an exceptional leadership team and 46 professionals with expertise in capital markets. The combined business will be led by Peter Winther, CEO and Jeppe Schønfeld who will serve as Deputy CEO of Colliers International in the region.

"Following our recent acquisition of the market leader in Finland earlier in the year, this merger establishes Colliers as the dominant player in another key Nordic market," said Chris McLernon, CEO, Colliers International | EMEA.  "We are going from strength to strength with the addition of these talented professionals establishing Colliers as one of the strongest pan-Nordic commercial real estate platforms anywhere."

"Our entrepreneurial culture and keen focus on service excellence has long been the key to our success, we are excited to partner with Colliers International, an organization that shares our entrepreneurial culture and keen focus on service excellence, along with a vision for the future focused on leveraging their well established enterprising business model," said Peter Winther CEO, Colliers | Denmark. "We look forward to taking full advantage of the Colliers International global brand and service platform while accelerating the success of our clients domestically and internationally." 

"Our entire team in Denmark is thrilled with this new development. The addition of experienced professionals in capital markets and research & valuation allows us to offer our clients additional best-in-class services throughout Denmark," said Jeppe Schønfeld, Deputy CEO, Colliers | Denmark.

About Colliers International Group Inc.

Colliers International Group Inc. (NASDAQ:CIGI) (TSX:CIGI) is an industry-leading real estate services company with a global brand operating in 69 countries and a workforce of more than 12,000 skilled professionals serving clients in the world's most important markets. Colliers is the fastest-growing publicly listed global real estate services company, with 2017 corporate revenues of $2.3 billion ($2.7 billion including affiliates). With an enterprising culture and significant employee ownership and control, Colliers professionals provide a full range of services to real estate occupiers, owners and investors worldwide. Services include strategic advice and execution for property sales, leasing and finance; global corporate solutions; property, facility and project management; workplace solutions; appraisal, valuation and tax consulting; customized research; and thought leadership consulting.

Colliers professionals think differently, share great ideas and offer thoughtful and innovative advice that help clients accelerate their success. Colliers has been ranked among the top 100 global outsourcing firms by the International Association of Outsourcing Professionals for 13 consecutive years, more than any other real estate services firm. Colliers has also been ranked the number one property manager in the world by Commercial Property Executive for two years in a row.

For the latest news from Colliers, visit Colliers.com or follow us on Twitter: @Colliers and LinkedIn.

COLLIERS CONTACTS:

John B. Friedrichsen
Chief Financial Officer
(416) 960-9500

Chris McLernon 
Chief Executive Officer | EMEA
(44) 207 487-7007




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Colliers International Group Inc. via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Apellis Pharmaceuticals Presents Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at 24th European Hematology Association (EHA) Congress15.6.2019 16:00:00 CESTPressemelding

CRESTWOOD, Ky. and WALTHAM Mass., June 15, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced updated data from its Phase 2 PLAUDIT study of APL-2 in patients with autoimmune hemolytic anemia (AIHA), including cold agglutinin disease (CAD) and warm antibody autoimmune hemolytic anemia (wAIHA). Data from the PLAUDIT trial will be presented in an oral presentation today at the 24th Annual Congress of the European Hematology Association (EHA), held in Amsterdam, the Netherlands. In the ongoing PLAUDIT study, 13 patients with CAD have been enrolled to receive subcutaneous APL-2 treatment, of which 10 patients have been on APL-2 for at least 168 days. The trial has also enrolled 11 patients with wAIHA, 8 of which were Direct Antiglobulin Test (DAT) C3+ (C3+ wAIHA); 5 of the C3+ wAIHA patients

Carpenter Technology and BMT Aerospace Combine Expertise in Redesign and Production of Additively Manufactured Aerospace Component14.6.2019 15:17:00 CESTPressemelding

LE BOURGET, France, June 14, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology Corporation (NYSE:CRS) and Belgium-based BMT Aerospace today announced their cooperation in the development of an additively manufactured (AM) aerospace pinion, using Carpenter Technology’s Custom 465® Stainless. BMT Aerospace and its subsidiary BMT Additive initiated the project by partnering with Carpenter Technology to produce a redesigned pinion. The redesign project was initiated to enable the benefits of additive manufacturing using high quality, printable material that would attain the high-performance expectations for the application. “BMT Aerospace strongly believes in the disruptive potential of additive manufacturing and its possibilities in aerospace,” explained Ewald Goossens, Business Unit Manager of BMT Additive. “As a small player in the market, we strongly believe in cooperation opportunities like these, where each partner can rely and build on a project, starting from its own expertise. Our spe

Immunophotonics and Clinical Laserthermia Systems Announce Immuno-Oncology Research Collaboration and Clinical Trials for Cancer Patients with Solid Tumors14.6.2019 13:00:00 CESTPressemelding

Collaboration will Combine Immunophotonics’ Proprietary Drug, IP-001, and CLS’s TRANBERG Laser Thermal Therapy System and imILT Method ST. LOUIS and LUND, Sweden, June 14, 2019 (GLOBE NEWSWIRE) -- Immunophotonics, Inc. and Clinical Laserthermia Systems, AB (STO:CLS B) (CLS) today announced they have entered into a research collaboration agreement to support a Phase 1b/2a clinical trial for cancer patients with certain solid tumor indications. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. Eligible patients with solid tumors will be treated using the locally administered CLS Immunostimulating Interstitial Laser Thermotherapy (imILT) method, followed immediately by an intratumoral injection of Immunophotonics’ lead asset, IP-001. Under the agreement, the CLS TRANBERG Laser and single-use products will be used in eligible patients enrolle

iCAD Introduces ProFound AI™ for 2D Mammography in Europe13.6.2019 14:00:00 CESTPressemelding

Company to showcase its newest artificial intelligence software solution, ProFound AI for 2D Mammography, in addition to ProFound AI for Digital Breast Tomosynthesis at the SIFEM Medical Conference in France NASHUA, N.H. and LILLE, France, June 13, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the launch of ProFound AI™ for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence platform and follows the launch of ProFound AI™ for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and FDA cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth (#24) at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference from June 13-15, 2019 at the Grand Palais in Lille, France. “iCAD is at the forefront of the fight ag

Telix Pharmaceuticals and Eczacıbaşı-Monrol Sign Manufacturing and Distribution Agreement13.6.2019 13:54:00 CESTPressemelding

MELBOURNE, Australia and ISTANBUL, Turkey, June 13, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR) has today announced that it has concluded a master services and distribution agreement with Eczacıbaşı-Monrol. Under the terms of the agreement, Telix has appointed Eczacıbaşı-Monrol as a radiopharmaceutical production partner and distributor in Turkey/Middle East/North Africa. Eczacıbaşı-Monrol is commercially active in more than 40 countries, including important growth territories that complement Telix’s current commercial strategy for the US and Europe. The parties will initially focus on the production and distribution of TLX250-CDx (89Zr-girentuximab) for imaging of renal cell carcinoma with Positron Emission Tomography (PET), including to support the ad

Highly Accurate Long-Read Sequencing of Human Genomes Leads to Discovery of Disease-Causing Variants13.6.2019 13:30:00 CESTPressemelding

Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif., June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large number that are left unexplained. Recently, scientists have adopted Single Molecule, Real-Time (SMRT®) Sequencing from Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, to study previously unsolved diseases. Many high-impact research publications report expanded variant detection in human genomes, leading to discovery of disease-causing variants and genes underlying rare and Mendelian disorders. In a Nature Communications publication, scientists report that most structural variants (SVs) and large indels are undetected in today’s human genetic studies, which likely accounts for some of the missing heritabi